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Background & Aims: Alterations in the serum levels of bile acids are associated with 60 
drug-induced liver injury (DILI). We investigated the association between serum 61 
levels of bile acids and the severity and outcome of DILI, along with the potential role 62 
of variants in the ATP binding cassette subfamily B member 11 (ABCB11) gene and 63 
expression of its product, ABCB11 (also called BSEP).  64 
Methods: We performed this prospective study of 95 patients (median age, 53 years; 65 
73.7% female) with DILI from August 2018 through August 2019. Patients were 66 
matched for age, gender, and body mass index with healthy individuals (n=100; 67 
healthy controls) and patients with chronic hepatitis B (n=105; CHB controls). We 68 
collected demographic and biochemical data at baseline and 1 week, 1 month, 3 69 
months, and 6 months after DILI onset and at the time of biochemical recovery, liver 70 
failure or liver transplantation. Serum levels of bile acids were measured using 71 
high-performance liquid-chromatography tandem mass-spectrometry. All 27 exons of 72 
ABCB11 were sequenced and expression of BSEP were analyzed by 73 
immunohistochemistry in liver biopsy specimens. 74 
Results: Levels of 30 of the 37 bile acids analyzed differed significantly between 75 
patients with DILI and healthy controls. Changes in levels of taurocholic acid (TCA), 76 
glycocholic acid, taurochenodeoxycholate, and glycochenodeoxycholate associated 77 
with the increased levels of bilirubin and greater severity of DILI, and were also 78 
associated with CHB. Cox regression analysis showed that only change in the levels 79 
of TCA independently associated with biochemical resolution of DILI. Combination 80 
of TCA level (≥ 1955.41 nmol/L), patient age, and DILI severity was as ociated with 81 
abnormal blood biochemistry at 6 months after DILI onset (area under the curve, 0.81; 82 
95% confidence interval, 0.71–0.88; sensitivity, 0.69; specificity, 0.81). ABCB11 83 
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missense variants were not associated with differences in the serum bile acid profiles, 84 
DILI severity, or clinical resolution. However, lower levels of BSEP in bile canaliculi 85 
in liver biopsies were associated with altered serum levels of bile acids. 86 
Conclusions: In this prospective study performed in Chinese patients, we found that 87 
the serum levels of TCA were associated with the severity and clinical resolution of 88 
DILI. Reduced protein expression of BSEP in liver tissue, rather than variants of the 89 
ABCB11 gene were associated with altered serum levels of bile acids. 90 
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Drug-induced liver injury (DILI) is one of the most common causes of clinically 95 
significant liver injury, with an annual incidence of 14-24 per 100,000 person-years 96 
worldwide[1-3]. DILI can have different phenotypes with diverse clinical features and 97 
variable outcomes. Cholestatic DILI is more prone to chronicity[4-6], whereas 98 
hepatocellular DILI has greater severity[7] and higher mortality once jaundice 99 
develops[8-11]. Although 87% of DILI patients achieve biochemical resolution within 6 100 
months after withdrawal of the offending drug(s)[3], 8% still have biochemical 101 
abnormalities within 12 months[12], leading to chronicity or even cirrhosis. 102 
Histological characteristics could aid in the prediction of clinical outcomes[4-6, 13, 14]. 103 
However, other noninvasive serum biomarkers are urgently needed in routine clinical 104 
practice. 105 
Recent evidence has shown that bile acid (BA) dysregulation plays a pivotal role 106 
in DILI, as bile excretion is the major route to eliminate bilirubin and some potentially 107 
harmful exogenous lipophilic substances[15, 16]. Animal studies have highlighted the 108 
diagnostic, prognostic and therapeutic importance of BAs in DILI[17-22]. In a human 109 
study, serum glycodeoxycholic acid level showed prognostic value in 110 
acetaminophen-induced acute liver failure (ALF)[23]. More recently, Ma et al. found 111 
that the serum BA levels could serve as potential biomarkers for the diagnosis and the 112 
distinction of mild from severe DILI[24].  113 
However, the association of altered BA profiles with the severity and prognosis of 114 
DILI warrants further verification. In addition, the potential mechanism of this 115 
7 
 
probable association remains unknown, although previous studies have illustrated the 116 
essential role of the bile salt export pump (BSEP), encoded by the ATP binding 117 
cassette subfamily B member 11 (ABCB11) gene, in DILI[25, 26]. 118 
In this prospective study, we investigated the differences in BA profiles in DILI 119 
patients, healthy controls, and chronic hepatitis B (CHB) patients. Then, we explored 120 
the association of altered BA profiles with clinical phenotypes and the severity and 121 
resolution of DILI. Finally, we explored the potential roles of ABCB11 gene variants 122 
and the liver expression of ABCB11 (BSEP) in the pathogenesis of altered serum BA 123 
profiles. 124 
  125 
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Materials and Methods 126 
Study population 127 
In this single-center cohort study, we prospectively recruited patients with a 128 
clinical diagnosis of DILI at Beijing Friendship Hospital, Capital Medical University, 129 
from August 2018 to August 2019. 130 
The inclusion criteria were as follows: (1) Chinese Han nationality aged 18 to 78 131 
years; (2) outpatients or inpatients with a diagnosis of DILI; and (3) available blood 132 
samples from the acute phase (within 10 days of obtaining the peak value of 133 
transaminase or bilirubin). 134 
The exclusion criteria were as follows: (1) other underlying liver disease or 135 
systemic diseases affecting the liver; (2) treatment with ursodeoxycholic acid, steroids, 136 
antibiotics or probiotics two weeks prior to the collection of blood samples; (3) a 137 
steroid-dependent state; (4) cirrhosis; and (5) loss to follow-up before the study 138 
endpoints. 139 
The diagnosis of DILI was re-ascertained[9] by three hepatologists (QT, RY, and 140 
LW) using Roussel Uclaf Causality Assessment Method (RUCAM) score ≥3 141 
(“possible”, “probable” or “highly probable” DILI). Based on the R value [ratio of 142 
alanine aminotransferase and alkaline phosphatase with their upper limits of normal 143 
(ULN)] at disease onset, DILI patients were categorized as having hepatocellular 144 
(R≥5), cholestatic (R≤2), or mixed (2<R<5) biochemical phenotypes[8]. The disease 145 
severity was evaluated according to previously reported criteria[9]. 146 
Follow-up information was collected at 1 week, 1 month, 3 months, and 6 months 147 
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after onset until biochemical recovery[6]. The clinical outcomes in this study included 148 
biochemical recovery, liver failure or liver transplantation. 149 
Age-, gender- and body mass index-matched healthy individuals and a CHB 150 
cohort at the same hospital were enrolled as controls (Supplementary Material 1). 151 
This study was approved by the Institutional Ethical Review Board of the Beijing 152 
Friendship Hospital, Capital Medical University [2018-P2-116-02]. All participants 153 
gave informed consent. 154 
Measurements of serum BAs 155 
Fasting serum samples from DILI patients during the acute phase and samples 156 
obtained from healthy controls and CHB patients were collected and frozen at -80°C 157 
for the subsequent BA measurement. Comprehensive quantitation of serum BAs was 158 
performed with high-performance liquid chromatography tandem mass 159 
spectrometry[27] at Metabo-Profile Inc. (Shanghai, China), which was blinded to any 160 
clinical information (Supplementary Material 2). 161 
Sanger sequencing of all 27 coding exons of the ABCB11 gene 162 
Peripheral blood mononuclear cells from the enrolled DILI patients and healthy 163 
controls were collected. Forward and reverse Sanger sequencing of all 27 coding 164 
exons of the ABCB11 gene and the associated boundary regions (adjacent sequences 165 
in introns) were conducted (Supplementary Material 3 & Supplementary Table 1).166 
Immunohistochemical evaluation of BSEP 167 
Percutaneous liver biopsies of DILI patients were fixed in formalin, embedded in 168 
paraffin, and sectioned at a thickness of 4 µm. BSEP expression was evaluated with 169 
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immunohistochemistry with antibody obtained from Santa Cruz Biotechnology 170 
(Shanghai) Co., Ltd., China (Supplementary Material 4). 171 
Semiquantitative evaluation of BSEP staining was conducted by two liver 172 
pathologists (XZ and JL) microscopically. Normal expression was defined as no loss 173 
or a mild loss (≤1/3) of BSEP expression, and reduced expression was defined as an 174 
obvious loss (>1/3) of BSEP expression. Quantitative evaluation of BSEP expression 175 
with Image-Pro Plus 6.0 (Media Cybernetics, Inc.) was conducted by a hepatologist 176 
(QT) with pathology training who was blinded to the patient data. 177 
Statistical analysis 178 
Categorical variables were expressed as counts or percentages, and continuous 179 
variables were expressed as the means ± standard deviations or medians and 180 
interquartile ranges. Comparisons of different groups were performed using the 181 
chi-square test, analysis of variance or the Kruskal-Wallis test; a Cox regression 182 
model was used to identify potential risk factors associated with clinical resolution, 183 
and Kappa statistics were used to assess the agreement. These analyses were 184 
conducted with SPSS 24.0 (SPSS Inc., Chicago, IL). 185 
The bioinformatic analysis was conducted using R 3.6.1 (R Foundation for 186 
Statistical Computing Platform). 187 
The difference in diagnostic performance was assessed using receiver operating 188 
characteristic (ROC) curves; the area under the ROC (AUROC) values were 189 








Clinical characteristics of DILI patients, healthy controls and CHB patients 194 
This study included 95 DILI patients, 100 healthy controls (Fig. 1) and 105 195 
noncirrhotic CHB patients. Age, gender, and BMI were comparable among three 196 
groups. The demographic, biochemical and clinical characteristics are summarized in 197 
Table 1 and Supplementary Table 2-3. 198 
The median age of DILI patients was 53 years, and the majority (73.7%) were 199 
females. Based on the R value, 63, 17 and 15 cases were defined as having a 200 
hepatocellular, cholestatic and mixed phenotype, respectively. According to the 201 
severity evaluation, all patients were categorized as 38 mild (Grade 1), 13 moderate 202 
(Grade 2), 40 severe (Grade 3), 3 liver failure (Grade 4) and 1 fatal (Grade 5). 203 
The median RUCAM score was 6. The majority (74.7%) of DILI cases were 204 
attributed to the use of herbs (Supplementary Material 5 and Supplementary Table 205 
4). The median biochemical recovery time was 88 days; 79 cases resolved at 6 months, 206 
and 86 cases resolved at 12 months. 207 
The BA profiles in DILI patients were significantly different from those in 208 
healthy controls 209 
As illustrated by the principal component analysis (PCA) (Supplementary Fig. 210 
1A), distinct clustering with minimal overlap was observed between DILI patients and 211 
healthy controls. Of the 37 measured BAs, the levels of 30 BAs were significantly 212 
different between DILI patients and healthy controls (Supplementary Table 5). The 213 
top six most significantly changed BAs with the strongest predictive ability (AUROC > 214 
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0.96) for distinguishing DILI patients from healthy controls are depicted in 215 
Supplementary Fig. 1B & C. 216 
BA profiles were comparable among DILI patients with different biochemical 217 
phenotypes and with different insulting agents 218 
DILI patients with hepatocellular, cholestatic and mixed phenotypes were 219 
comparable in terms of age, gender, and BMI (Table 1). The serum BA profiles could 220 
not be distinguished among the three phenotypes based on the PCA plot (Fig. 2A). 221 
Further analysis of the level of each BA showed that they were generally comparable 222 
across the three phenotypes. 223 
Details of insulting agents are listed in Supplementary Table 4. We divided the 224 
DILI patients into three groups according to the types of insulting agents: herbs, 225 
conventional medicine and a combination of herbs and conventional medicine. As the 226 
PCA plot showed, the serum BA profiles in these groups largely overlapped 227 
(Supplementary Fig. 2). Further analysis also showed similar BA levels among these 228 
groups. 229 
BA levels increased with the serum bilirubin level and could be used to 230 
distinguish the severity of DILI 231 
The levels of five BAs, namely, taurocholic acid (TCA), glycocholic acid (GCA), 232 
taurochenodeoxycholate (TCDCA), glycochenodeoxycholate (GCDCA) and 233 
glycoursodeoxycholic acid (GUDCA), showed an increasing trend along with the 234 
serum bilirubin levels (total bilirubin <5 ULN, 5-10 ULN, 10-20 ULN and >20 ULN) 235 
(Fig. 2B). 236 
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Further analysis of the BA profiles in the mild (N=38), moderate (N=13), and 237 
severe/liver failure/fatal (N=44) groups of DILI patients revealed that a subgroup of 238 
BAs could distinguish different groups, as shown in the Venn diagram (Fig. 2C), and 239 
the details regarding the BAs are listed in Supplementary Table 6. Specifically, TCA, 240 
GCA, TCDCA and GCDCA could credibly determine the degree of DILI severity, as 241 
they proportionately rose with an increase in severity (Fig. 2D).242 
Notably, four patients with dismal prognoses had strikingly high TCA levels: 243 
10152.46 nmol/L (ALF; received artificial liver support), 13742.13 nmol/L (ALF; 244 
recovered 66 days after drug withdrawal), 28537.60 nmol/L (ALF; received artificial 245 
liver support) and 26136.74 nmol/L (received liver transplantation), further 246 
corroborating the prognostic implications of serum TCA in DILI patients, as the 247 
median value of TCA in the whole DILI cohort was 1955.41 nmol/L. 248 
Serum TCA was an independent factor that predicted the timing of disease 249 
resolution and could improve the prediction of the 6-month outcome in DILI 250 
patients 251 
We assessed the role of clinical features (age, gender, BMI, and severity) and BA 252 
profiles in predicting the clinical course (days to biochemical normalization) with 253 
proportional Cox regression. TCA was found to be the only independent factor 254 
associated with biochemical resolution (Table 2). 255 
We then analyzed the predictive ability of age, severity, TCA, and their 256 
combination for assessing the 6-month outcome (abnormal biochemistry). The 257 
AUROC values for age, severity, TCA, and their combination were 0.58, 0.65, 0.69 258 
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and 0.81, respectively (Fig. 2E; Table 3). 259 
High serum TCA level alone could be a potential useful indicator for predicting 260 
6-month abnormal biochemistry outcome with an optimal cut-off value of 1955.41 261 
nmol/L (~2 µmol/L) (AUROC=0.69, sensitivity=0.81, specificity=0.57). Furthermore, 262 
the combination of TCA, severity and age had a better predictive ability for the 263 
6-month outcome, with an AUROC value of 0.81 and a sensitivity and specificity of 264 
0.69 and 0.81, respectively (Table 3). 265 
Changes in serum BAs along with serum bilirubin were also observed in CHB 266 
patients 267 
The levels of several BAs, including TCA, were significantly different among 268 
healthy controls, CHB patients and DILI patients. They showed a stepwise significant 269 
increase in CHB and DILI patients compared with those in healthy controls 270 
(Supplementary Table 7). 271 
 Totally, the levels of seven BAs were increased along with serum bilirubin in 272 
CHB patients (Supplementary Table 8). Four out of these seven BAs, i.e., TCA, 273 
GCA, TCDCA, and GCDCA, were also increased along with serum bilirubin in DILI 274 
patients (Supplementary Fig. 3). 275 
 Although the TCA level was significantly lower in CHB patients than that in 276 
DILI patients, its increase along with serum bilirubin was similar to that observed in 277 
DILI patients. In addition, three CHB patients with acute on chronic liver failure had 278 
extremely high serum TCA levels of 15101.88 nmol/L, 11734.34 nmol/L and 7621.98 279 
nmol/L, while the median value of TCA level in the CHB cohort was 80.14 nmol/L. 280 
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These results suggested that TCA was increased along with serum bilirubin and may 281 
be associated with liver failure without DILI specificity. 282 
Genetic variants of ABCB11 did not account for serum BA alterations or the 283 
severity or clinical resolution of DILI 284 
The genetic variants in ABCB11 gene are listed in Supplementary Table 9. The 285 
frequencies of all ABCB11 missense variants in DILI patients were not significantly 286 
different from those in healthy Chinese controls. A total of 71 DILI patients (74.7%) 287 
had missense variants of ABCB11; however, they had comparable serum BA profiles, 288 
severity scores, and time to resolution with the remaining 24 DILI cases not having 289 
any ABCB11 missense variant (Fig. 3A & B). 290 
Reduced liver expression of BSEP was associated with serum BA alterations and 291 
disease severity 292 
Liver biopsies were performed in 34 of the 95 DILI patients. The biopsied 293 
patients had comparable baseline characteristics with the remaining patients who 294 
declined biopsy (Supplementary Table 10). Hence, the biopsied patients were 295 
considered representative of the entire DILI cohort. Based on semiquantitative 296 
assessment by the liver pathologists, BSEP expression was ranked as either normal or 297 
reduced (Fig. 3C & D). The semiquantification of BSEP expression was validated by 298 
quantification analysis (indexed as the mean integrated optical density using 299 
Image-Pro Plus), which resulted in good interobserver agreement (kappa value 0.90). 300 
The 11 DILI cases with reduced BSEP expression had significantly higher BA 301 
levels (including TCA, GCA and GCDCA) compared with the remaining 23 cases 302 
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with normal BSEP expression (Fig. 3E). In addition, severe DILI was observed in 64% 303 
versus 26% of DILI cases with reduced and normal BSEP expression, respectively 304 




In this study, we found that the levels of certain conjugated BAs increased in a 307 
stepwise manner along with DILI severity. Furthermore, the level of serum TCA was 308 
independently associated with the clinical resolution of DILI. The alteration of serum 309 
BAs was associated with reduced liver expression of BSEP but not with genetic 310 
variants of ABCB11, encoding BSEP. Taken together, these results suggest that a high 311 
serum TCA level is positively associated with disease severity and can potentially 312 
predict the clinical resolution of DILI patients. 313 
In our study, TCA, GCA, TCDCA and GCDCA were found to increase along 314 
with disease severity. This is in line with a previous study that showed similar 315 
disruptions of BA levels, serving as biomarkers for the differentiation of severe and 316 
mild DILI [24]. Similarly, Woolbright et al. found that serum glycodeoxycholic acid 317 
could predict the survival of acetaminophen-induced ALF patients[23]. All these 318 
evidences shed light on the role of BAs in identifying high-risk DILI. Our study 319 
suggested that routinely serum test for these BAs would aid in the identification of 320 
DILI patients with greater severity or at higher risk of liver failure so that additional 321 
supportive/preventive measures could be initiated. 322 
Moreover, our study revealed that the TCA level, as tested during the acute phase, 323 
was an independent risk factor for biochemical resolution in DILI. The TCA level 324 
alone had a similar predictive performance for the 6-month abnormal biochemistry 325 
outcome as the current constellation of severity assessment. Since the DILI severity 326 
discrimination is based on a group of parameters, including: symptoms, serum 327 
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bilirubin, blood clotting tests, hospitalization and organ dysfunction [9, 10, 28-30], 328 
measurement of the serum TCA level may serve as a new biomarker for DILI 329 
stratification and outcome prediction. In fact, when TCA measurement was added to 330 
the current outcome assessment, the predictive performance for DILI resolution 331 
improved from 0.75 for severity-age to 0.81[31] for TCA-severity-age, although the 332 
difference was not statistically significant. It is worth noting that the increase in serum 333 
TCA, GCA, TCDCA and GCDCA along with serum bilirubin in both DILI and CHB 334 
patients might suggest that the alteration of these BAs was not disease-specific. 335 
In addition, we found that missense variants of ABCB11 were not associated with 336 
serum BA alterations, disease severity or days to resolution in DILI. This finding was 337 
also consistent with those of large-cohort genome-wide association studies, which did 338 
not find genetic susceptibility of ABCB11 in multiple-drug-induced liver injury [32, 33]. 339 
This may serve as a strong evidence that DILI is indeed an acquired instead of inborn 340 
disease[34]. Nevertheless, we did show that the alteration of BA profiles was partially 341 
due to the reduced expression of BSEP, a protein encoded by the ABCB11 gene and 342 
the molecule responsible for pumping bile salts from the hepatocellular cytoplasm 343 
into the bile canaliculi[16]. Our findings suggest that reduced protein expression of 344 
BSEP in DILI patients may occur during transcriptional and/or translational processes 345 
and/or due to the interactions between the host and the drug[35, 36], which warrants 346 
further in-depth investigation. 347 
The strength of this study is that it offers clinical evidence that routine 348 
measurement of certain serum BAs may improve the identification of high-risk DILI 349 
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patients and the prediction of clinical outcomes. Furthermore, we revealed that the 350 
underlying mechanism of the altered BA profiles was not due to ABCB11 genetic 351 
variants but instead to reduced BSEP expression at the protein level. 352 
However, the conclusion from this single-center prospective study of Chinese 353 
Han individuals with a moderate sample size needs further validation in multicenter 354 
studies. Furthermore, only 36% of the entire DILI cohort had a liver biopsy available 355 
for BSEP analysis, which may introduce possible selection bias. However, there was 356 
no significant difference in the demographic and major clinical profiles between those 357 
with and without liver biopsies; thus, we hope the BSEP immunohistochemical 358 
staining results to be interpreted as representative of the entire DILI cohort. 359 
In conclusion, the serum levels of the conjugated BAs TCA, GCA, TCDCA and 360 
GCDCA showed a strong association with the severity of DILI. Specifically, TCA is 361 
an important biomarker that is associated with clinical resolution and can improve the 362 
prediction of the 6-month biochemical resolution outcome. The alteration of BA 363 
profiles is not due to ABCB11 genetic variants but is due to reduced BSEP protein 364 
expression. The present findings provide further evidence that determination of the 365 
BA profile may help to optimize the management of DILI in clinical practice. 366 
  367 
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Figure Legends: 368 
Fig. 1 Enrollment of DILI patients and healthy control subjects.1 369 
Fig. 2 The exploration of BAs in association with severity and days to resolution. 370 
Overall, the levels of serum BAs in DILI patients with different biochemical 371 
phenotypes could not be distinguished as separate clusters via principal component 372 
analysis (A); TCA, GCA, TCDCA, GCDCA and GUDCA levels showed gradually 373 
increasing trends along with serum bilirubin levels (B); a subgroup of BAs could 374 
distinguish different severities of DILI (C); TCA, GCA, TCDCA and GCDCA rose in 375 
proportion with the increases of severity (D); the diagnostic performance of different 376 
indexes for predicting the 6-month abnormal biochemistry (E). 2 377 
Fig. 3 Role of ABCB11/BSEP in BA profiles, severity, and days to resolution in 378 
DILI patients. Overall BA levels were comparable in DILI patients with or without 379 
ABCB11 missense variants (A); DILI patients with or without ABCB11 missense 380 
variants had comparable severities and days to resolution (B); examples of normal (C) 381 
and reduced (D) BSEP expression (immunohistochemical staining, 200×); DILI 382 
patients with reduced BSEP expression showed greater alteration of BA profiles  383 
compared with those with normal BSEP expression(E) and a higher risk of having a 384 
severe case (F); however, they had a similar number of days to resolution. No 385 
significant difference in BSEP expression was found between patients with and 386 
                                                  
1 HBV, hepatitis B virus; NAFLD,  nonalcoholic fatty liver disease; PBC, primary biliary cholangitis, SSC, secondary sclerosing 
cholangitis. 
2 GCA, glycocholic acid; GCDCA, glycochenodeoxycholate; GUDCA, glycoursodeoxycholic acid; PC, principal component; 
TBil,  total bilirubin; TCA, taurocholic acid; TCDCA, taurochenodeoxycholate; ULN,  upper limit of normal. 
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without ABCB11 missense variants.3  387 
  388 
                                                  
3 GCA, glycocholic acid; GCDCA, glycochenodeoxycholate; GHCA, glycohyocholate; Missense (-), DILI patients without any 
ABCB11 missense variant(s); Missense (+), DILI patients with ABCB11 missense variant(s); Normal BSEP, DILI patients with 
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Table 1 Demographics and baseline characteristics of healthy controls and DILI 




Overall DILI Hepatocellular (R ≥5) Mixed (2<R<5) Cholestatic (R≤2) 
P value# 
(N=100) (N=95) (N=63) (N=15) (N=17) 
Age (years) 47 (45, 55) 53 (40, 63) 50 (38, 61) 63 (43, 66) 51 (48, 62)  .13 
Female, N (%) 67 (67.0) 70 (73.7) 47 (74.6) 9 (60.0) 14 (82.4)  .34 
BMI (kg/m 2) 
23.19 (21.63, 
25.50) 
22.75 (20.08, 25.00) 22.80 (20.15, 25.10) 23.20 (21.03, 25.03) 21.70 (19.50, 24.00)  .45 
ALT (IU/L) 27 (20, 33) 492 (172, 1026) 808 (475, 1294) 192 (111, 349) 58 (35, 79) < .001 
AST (IU/L) 28 (21, 33) 311 (110, 709) 479 (264, 1020) 132 (109, 278) 57 (43, 79) < .001 
ALP (IU/L) 91 (67, 117) 201 (126, 262) 175 (112, 223) 277 (124, 387) 246 (198, 406)  .004 
GGT (IU/L) 35 (29, 43) 178 (96, 298) 169 (89, 261) 187 (87, 554) 215 (106, 307)  .46 
TBil (µmol/L) 13 (10, 16) 60 (21, 187) 54 (21, 146) 165 (45, 245) 61 (19, 227)  .23 




31.85 (11.19, 151.06) 26.65 (9.80, 148.68) 29.57 (10.63, 112.70) 120.81 (15.89, 248.57)  .10 
Albumin (g/L) NT 38.4±5.0 38.9±5.1 37.5±4.2 37.4±5.3  .56 
Globulin (g/L) NT 30.5±6.8 32.1±7.3 30.9±8.3 28.5±5.7  .40 
IgG (mg/dl) NT 1312.9±343.1 1369.5±307.8 1309.5±580.5 1221.9±379.4  .65 
IgM (mg/dl) NT 98.10 (70.68, 139.40) 93.55 (66.08, 140.00) 101.00 (75.40, 130.00) 108.00 (79.30, 146.00)  .37 
INR NT 1.11 (1.01, 1.23) 1.12 (1.03, 1.23) 1.14 (0.89, 1.27) 1.04 (0.94, 1.30)  .64 
ANA NT 
    
NA 
  Negative 
 
64 (67.4) 46 (73.0) 10 (66.7) 8 (47.1)   
  1:80 positive 
 
20 (21.1) 11 (17.5) 2 (13.3) 7 (41.2)   
  1:160 positive 
 
10 (10.5) 5 (7.9) 3 (20.0) 2 (11.8)   
  1:320 positive 
 
1 (1.1) 1 (1.6) 0 (0) 0 (0)   
Negative AMA-M2 (N, %) NT 95 (100) 63 (100) 15 (100) 17 (100) NA 
Ceruloplasmin (g/L) NT 0.30 (0.24, 0.35) 0.29 (0.24, 0.34) 0.29 (0.23, 0.42) 0.34 (0.24, 0.53)  .27 
Ferritin (ng/mL) NT 205.95 (128.33, 369.00) 212.90 (104.90, 373.40) 322.20 (162.00, 530.80) 133.45 (98.53, 185.10)  .022 
TS (%) NT 46.93 ± 19.28 48.65 ± 21.36 48.35 ± 14.07 36.56 ± 10.23 .16 
AFP (ng/mL) NT 3.90 (2.90, 6.24) 4.17 (2.98, 8.14) 3.56 (2.40, 4.44) 3.41 (2.60, 5.13)  .109 
WBC (×109/L) 7.1±1.9 5.6±2.1 5.7±2.2 5.7±1.2 5.5±2.5  .98 
Platelets (×109/L) 194.4±59.6 203.2±58.3 210.6±56.5 192.8±55.9 184.8±67.7  .65 
Hemoglobin (g/L) 128.8±8.4 132.4±17.0 135.0±16.8 133.4±13.4 123.2±18.4  .34 
RUCAM score NT 6 (5, 7) 7 (6, 8) 5 (4, 6) 4 (4, 6) < .001 
Severity score NT 2 (1, 3) 2 (1, 3) 3 (1, 3) 2 (1, 3)  .40 
2 
 
Footnote: #P value stands for the overall comparison of hepatocellular, mixed and cholestatic phenotype of DILI; AFP, alpha fetoprotein; 
ALP,  alkaline phosphatase; ALT, alanine aminotransferase; AMA-M2, anti-mitochondrial M2 antibody; ANA,  anti-nuclear antibody; 
AST, aspartate aminotransferase; BMI,  body mass index; DBil,  conjugated bilirubin; GGT, gamma-glutamyl transferase; Ig, 
immunoglobulin; INR,  international normalized ratio; NA, not available for statistically significance analysis; NT, not tested; RUCAM, 





Table 2 Serum TCA level was an independent risk factor for days to resolution 
by Cox-regression analysis 
Significant factors in univariate-analysis 
Univariate Multivariate 
HR (95% CI) P value HR (95% CI) P value 
Severity 0.75 (0.62, 0.91)  .004 0.90 (0.69, 1.16)  .41 
TBA (>31.85µmol/L vs. <31.85µmol/L) 0.65 (0.43, 0.98)  .041 0.83 (0.41, 1.67)  .59 
GCA (>5463.00nmol/L vs. <5463.00nmol/L) 0.58 (0.38, 0.88)  .010 0.49 (0.16, 1.5)  .21 
TUDCA (>1073.60nmol/L vs. <1073.60nmol/L) 0.56 (0.37, 0.85)  .007 1.06 (0.46, 2.42)  .90 
THCA (>109.65nmol/L vs. <109.65nmol/L) 0.59 (0.39, 0.89)  .013 0.89 (0.41, 1.93)  .76 
TCA (>1955.41nmol/L vs. <1955.41nmol/L) 0.47 (0.31, 0.73)  .001 3.04 (1.08, 8.58)  .036 
TLCA-3S (>360.40nmol/L vs. <360.40 nmol/L) 0.56 (0.37, 0.87)  .009 1.11 (0.65, 1.89)  .72 
NorCA (>22.29nmol/L vs. <22.29nmol/L) 0.58 (0.38, 0.87)  .009 1.40 (0.81, 2.41)  .22 
βCDCA (>23.03nmol/L vs. <23.03nmol/L) 1.82 (1.19, 2.78)  .006 0.75 (0.39, 1.44)  .39 
Footnote: βCDCA, 3β-chenodeoxycholic acid; CI, Confidence Interval; GCA, glycocholic acid; HR, Hazard Ratio; NorCA, nor cholic 





Table 3 Addition of serum TCA level could improve predictive ability of 6-month 









(95% CI), % 
Specificity 







P value when 






62.50 (35.40 - 
84.80) 
53.16 (41.60 - 
64.50) 





68.75 (41.30 - 
89.00) 
58.23 (46.60 - 
69.20) 






81.25 (54.40 - 
96.00) 
56.96 (45.30 - 
68.10） 






75.00 (47.60 - 
92.70) 
59.49 (47.90 - 
70.40) 







68.75 (41.30 - 
89.00) 
81.01 (70.60 - 
89.00) 
3.62 0.39 / 
Footnote: AUROC, areas under the receiver operating characteristic curves; CI, confidence interval; TCA, taurocholic acid. 
